Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$407.90 USD
-4.32 (-1.05%)
Updated Oct 15, 2025 04:00 PM ET
After-Market: $407.10 -0.80 (-0.20%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Vertex Pharmaceuticals Incorporated's dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
VRTX 407.90 -4.32(-1.05%)
Will VRTX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for VRTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRTX
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
Here's Why Vertex Pharmaceuticals (VRTX) Fell More Than Broader Market
VRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Other News for VRTX
VRTX's price rises by 1.19% on October 14, though its technical setup remains stable.
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
VRTX forms Non-ADX 1,2,3,4 Bullish on October 13
Vertex Pharmaceuticals (VRTX) Gets a Buy from Wells Fargo
Citi Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)